retatrutide molecule vs. Tirzepatide: The Next-Gen GLP-1 Showdown ADA 2026: Retatrutide Revolution

Anderson, FASAE, CAE, IOM President & Chief Executive Officer Date: June 4, 2026 Beginning July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) will launch the Medicare GLP-1 Bridge Program, a temporary demonstration designed to provide

Enhances overall metabolic efficiency

Discover how GLP-1 agonists help improve cardiovascular outcomes independently of glucose control.

When clients started asking me about Ozempic and Mounjaro, I pretty much tried to keep my head firmly in the sand

Yes, hydroxychloroquine has clinically significant interactions with escitalopram and potentially with bupropion (Wellbutrin), requiring cardiac monitoring a...

Leading Players in the GLP-1 Market Novo Nordisk 38.72% Ozempic Wegovy Rybelsus Eli Lilly 28.41% Mounjaro Zepbound Sanofi 8.76% 4 AstraZeneca 6.62% 5 GSK 4.95% 6 Regeneron 3.27% 7 Pfizer 2.61% 8 Amgen 1.98% 9 Sun Pharma 1.52% Boehringer Ingelheim 1.24% Together, Novo Nordisk and Eli Lilly account for more than 67% of the market, highlighting the intense competition between the two companies that currently lead the obesity and diabetes treatment revolution